Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 3, Issue , 2010, Pages

  Desouza, Cyrus V ^a,b   Shivaswamy, Vijay ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

cardiovascular; diabetes; efficacy; Pioglitazone; safety

Indexed keywords

EID: 85127246273     PISSN: None     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S5372     Document Type: Review

References (81)

1. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457–71.
2. Dormandy J.A., Charbonnel B., Eckland D.J. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279–89.
3. Wilcox R., Bousser M.G., Betteridge D.J. et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38: 865–73.
4. Mannucci E., Monami M., Lamanna C., Gensini G.F., Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008; 10: 1221–38.
5. Mazzone T., Meyer P.M., Feinstein S.B. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296: 2572–81.
6. Nissen S.E., Nicholls S.J., Wolski K. et al. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299: 1561–73.
7. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007; 298: 1180–8.
8. Tzoulaki I., Molokhia M., Curcin V. et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009; 339: b4731.
9. Spanheimer R., Betteridge D.J., Tan M.H., Ferrannini E., Charbonnel B. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol. 2009; 104: 234–9.
10. Bajaj M., Baig R., Suraamornkul S. et al. Effects of pioglitazone on intramyo-cellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 95: 1916–23.
11. Pershadsingh H.A. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs. 2004; 13: 215–28.
12. Rosmarakis E.S., Falagas M.E. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J. 2007; 154: 144–50.
13. Giaginis C., Tsantili-Kakoulidou A., Theocharis S. Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. PPAR Res. 2008: 431763.
14. Desouza C.V., Gerety M., Hamel F.G. Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. Vascul Pharmacol. 2007; 46: 188–94.
15. Aljada A., O'Connor L., Fu Y.Y., Mousa S.A. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis. 2008; 11: 361–7.
16. Takagi T., Okura H., Kobayashi Y. et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv. 2009; 2: 524–31.
17. Pfutzner A., Schondorf T., Hanefeld M., Forst T. High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone. J Diabetes Sci Technol. 4: 706–16.
18. Permana P.A., Zhang W., Wabitsch M., Fischer-Posovszky P., Duckworth W.C., Reaven P.D. Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages. Am J Physiol Endocrinol Metab. 2009; 296: E1076–84.
19. Hu Y.Y., Ye S.D., Zhao L.L., Zheng M., Chen Y. Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics. Eur J Clin Invest.
20. Glatz T., Stock I., Nguyen-Ngoc M. et al. Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens.
21. Huang P.H., Sata M., Nishimatsu H., Sumi M., Hirata Y., Nagai R. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother. 2008; 62: 46–52.
22. Gensch C., Clever Y.P., Werner C., Hanhoun M., Bohm M., Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 2007; 192: 67–74.
23. Vlckova V., Cornelius V., Kasliwal R., Wilton L., Shakir S.A. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf. 2009; 32: 409–18.
24. Jain R., Osei K., Kupfer S., Perez A.T., Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006; 26: 1388–95.
25. Meneghini L.F., Traylor L., Schwartz S. Improved Glycemic Control with Insulin Glargine vs. Pioglitazone as ADD-ON Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes. Endocr Pract. 2010 Mar 29: 1–6. [Epub ahead of print].
26. Charbonnel B., Defronzo R., Davidson J. et al. Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19). J Clin Endocrinol Metab. 2010 May; 95(5): 2163–71.
27. Basu A., Jensen M.D., McCann F., Mukhopadhyay D., Joyner M.J., Rizza R.A. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006; 29: 510–4.
28. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004; 351: 1106–18.
29. Giles T.D., Elkayam U., Bhattacharya M., Perez A., Miller A.B. Comparison of Pioglitazone vs. Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease. Congest Heart Fail. 2010 May 1; 16(3): 111–7.
30. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000; 23: 1605–11.
31. Czoski-Murray C., Warren E., Chilcott J., Beverley C., Psyllaki M.A., Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess. 2004; 8: iii, ix–x, 1–91.
32. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998; 338: 916–7.
33. Lebovitz H.E., Kreider M., Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002; 25: 815–21.
34. May L.D., Lefkowitch J.H., Kram M.T., Rubin D.E. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002; 136: 449–52.
35. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med. 2001; 135: 306.
36. Tolman K.G., Freston J.W., Kupfer S., Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009; 32: 787–800.
37. Abe M., Okada K., Maruyama T., Maruyama N., Soma M., Matsumoto K. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother. 2010 Jul;11(10): 1611–20.
38. Ryan E.H. Jr., Han D.P., Ramsay R.C. et al. Diabetic macular edema associated with glitazone use. Retina. 2006; 26: 562–70.
39. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005; 123: 1273–5.
40. Ciardella A.P. Partial resolution of diabetic macular oedema after systemic treatment with furosemide. Br J Ophthalmol. 2004; 88: 1224–5.
41. Shen L.Q., Child A., Weber G.M., Folkman J., Aiello L.P. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008; 126: 793–9.
42. Ambrosius W.T., Danis R.P., Goff DC Jr et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol. 2010 Mar;128(3): 312–8.
43. Standards of medical care in diabetes. Diabetes Care. 2010; 33 Suppl 1: S11–61.
44. Home P.D., Pocock S.J., Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125–35.
45. Schwartz A.V., Sellmeyer D.E., Vittinghoff E. et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006; 91: 3349–54.
46. Meier C., Kraenzlin M.E., Bodmer M., Jick S.S., Jick H., Meier C.R. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168: 820–5.
47. Habib Z.A., Havstad S.L., Wells K., Divine G., Pladevall M., Williams L.K. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010 Feb;95(2): 592–600.
48. Kasliwal R., Wilton L.V., Shakir S.A. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf. 2008; 31: 839–50.
49. Buchanan T.A., Xiang A.H., Peters R.K. et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002; 51: 2796–803.
50. Gerstein H.C., Yusuf S., Bosch J. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368: 1096–105.
51. Defronzo R.A., Banerji M., Bray G.A. et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009; 9: 17.
52. Scherbaum W.A., Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res. 2002; 34: 589–95.
53. Rosenblatt S., Miskin B., Glazer N.B., Prince M.J., Robertson K.E. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001; 12: 413–23.
54. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000; 22: 1395–409.
55. Kipnes M.S., Krosnick A., Rendell M.S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001; 111: 10–7.
56. Rosenstock J., Einhorn D., Hershon K., Glazer N.B., Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002; 56: 251–7.
57. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221–31.
58. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005; 42: 987–1000.
59. Ratziu V., Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology. 2006; 44: 802–5.
60. Ekstedt M., Franzen L.E., Mathiesen U.L. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 865–73.
61. Belfort R., Harrison S.A., Brown K. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355: 2297–307.
62. Sanyal A.J., Mofrad P.S., Contos M.J. et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004; 2: 1107–15.
63. Ratziu V., Giral P., Jacqueminet S. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135: 100–10.
64. Aithal G.P., Thomas J.A., Kaye P.V. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135: 1176–84.
65. Sanyal A.J., Chalasani N., Kowdley K.V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6; 362(18): 1675–85.
66. Ota H., Goto T., Yoshioka T., Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril. 2008; 90: 709–13.
67. Ghazeeri G., Kutteh W.H., Bryer-Ash M., Haas D., Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 2003; 79: 562–6.
68. Sarafidis P.A., Stafylas P.C., Georgianos P.I., Saratzis A.N., Lasaridis A.N. Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A meta-analysis. Am J Kidney Dis. 2010 May;55(5): 835–47.
69. Petrica L., Petrica M., Vlad A. et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr. 2009; 121: 765–75.
70. Fonseca V., Desouza C., Asnani S., Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev. 2004; 25: 153–75.
71. Aljada A., Shah K.A., Mousa S.A. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res. 2009: 460764.
72. Derosa G., D'Angelo A., Ragonesi P.D. et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther. 2006; 31: 375–83.
73. Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H.R., Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004; 89: 1140–5.
74. Yang T., Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res. 2008: 943614.
75. Lecka-Czernik B., Moerman E.J., Grant D.F., Lehmann J.M., Manolagas S.C., Jilka R.L. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002; 143: 2376–84.
76. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008; 19: 129–37.
77. Glintborg D., Andersen M., Hagen C., Heickendorff L., Hermann A.P. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008; 93: 1696–701.
78. Grey A., Bolland M., Gamble G. et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007; 92: 1305–10.
79. Berberoglu Z., Gursoy A., Bayraktar N. et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab. 2007; 92: 3523–30.
80. Zinman B., Haffner S.M., Herman W.H. et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010 Jan;95(1): 134–42.
81. McClain C.J., Mokshagundam S.P., Barve S.S. et al. Mechanisms of nonalcoholic steatohepatitis. Alcohol. 2004; 34: 67–79.